Treatment of hepatic metastases of colorectal cancer by robotic stereotactic radiation (Cyberknife (R)).

Date publication

avril 2014

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEIFFERT Didier

Tous les auteurs :
Peiffert D, Baumann AS, Marchesi V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/24582275

Résumé

Cyberknife((R)) is a dedicated stereotactic radiotherapy device. This new technology permits precise delivery of high dose gradient radiation therapy while sparing the surrounding organs at risk. Hepatic metastases of colorectal cancer (HMCRC) are an example of a lesion where treatment with Cyberknife((R)) is indicated because they are located in a radio-sensitive organ and curative treatment is based on focal eradication (resection, radiofrequency ablation,...). The local control rate at one year is reported to be 70 to 100% depending on the study. Tolerance is excellent with less than a 5% rate of acute grade 3 or 4 side effects (nausea, vomiting, gastro-duodenal ulcer). The specific hepatotoxicity of radiotherapy, so-called radiation-induced liver disease (RILD), was found in only one study. Candidates for stereotactic radiotherapy are patients in whom disease is controlled except for intrahepatic disease with 1-3 hepatic metastases

Référence

J Visc Surg. 2014 Apr;151 Suppl 1:S45-9